EXEL - Viela Bio Gets Approval And Other News: The Good Bad And Ugly Of Biopharma
Viela Bio Wins FDA Approval for Autoimmune Treatment
Viela Bio (VIE) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that nearly 80 percent of NMOSD patients are positive for anti-AQP4 antibodies. The drug candidate was given Breakthrough therapy and Orphan Drug tags by the FDA.
Viela had used the results from its pivotal N-MOmentum trial for supporting the application. It is one of the largest studies conducted in a real world